Part, Chapter, Paragraph
1 II, 5. 1. 1| colon, endometrial and kidney cancer and, through the
2 II, 5. 1. 1| elderly smokers.~Chronic Kidney Disease and End Stage Renal
3 II, 5. 4. 1| including vision loss, nerve and kidney damage), and larger blood
4 II, 5. 4. 1| ability and thus leading to kidney failure (necessitating renal
5 II, 5. 4. 2| extremity amputation rates~Kidney disease in persons with
6 II, 5. 4. 2| pressure, blood lipids, kidney functions and microalbuminuria.
7 II, 5. 4. 3| pressure, blood lipids, kidney functions and microalbuminuria.
8 II, 5. 7 | 5.7. Chronic kidney disease and end stage renal~
9 II, 5. 7.Acr| Communities~CKD~Chronic Kidney Disease~ESRD~End Stage Renal
10 II, 5. 7.Acr| Rate~HD~Haemodialysis~KDIGO~Kidney Disease Improving Global
11 II, 5. 7. 1| Introduction~ ~Chronic kidney disease (CKD) is increasingly
12 II, 5. 7. 1| treatment can prevent or delay kidney disease progression and
13 II, 5. 7. 1| Chobanian et al, 2003; National Kidney Foundation, 2002-2006; Sarnak
14 II, 5. 7. 1| definition established by the Kidney Disease Improving Global
15 II, 5. 7. 1| KDIGO Definition of Chronic Kidney Disease~ ~ ~Structural or
16 II, 5. 7. 1| months, as manifested by:~1. Kidney damage, with or without
17 II, 5. 7. 1| abnormalities~• markers of kidney damage~urinary abnormalities (
18 II, 5. 7. 1| imaging abnormalities~• kidney transplantation~2. GFR <
19 II, 5. 7. 1| 73 m2 , with or without kidney damage~ ~ ~ ~ ~Table 5.7.
20 II, 5. 7. 1| CM Code~ ~Treatment~ ~1~Kidney damage~with normal or higher
21 II, 5. 7. 1| GFR*~>90~585.1~1-5 T if kidney transplant recipient~ ~2~
22 II, 5. 7. 1| transplant recipient~ ~2~Kidney damage~with mild decrease
23 II, 5. 7. 1| in GFR*~15–29~585.4~ ~5~Kidney failure~<15~(or dialysis)~
24 II, 5. 7. 3| 2. Prevalence of chronic kidney disease per stage in two
25 II, 5. 7. 3| of stages 3-5 of chronic kidney disease in selected EUGLOREH
26 II, 5. 7. 3| of stages 3-5 of chronic kidney disease by age and sex.~ ~
27 II, 5. 7. 3| times as high as that after kidney transplantation: 60% and
28 II, 5. 7. 5| the problem {14 National Kidney Foundation, 2002 79 /id}.
29 II, 5. 7. 5| particularly during the World Kidney Day, in the last two years.~·
30 II, 5. 7. 5| the measurements of the kidney function and the introduction
31 II, 5. 7. 5| diabetes directly related to kidney disease. This significantly
32 II, 5. 7. 5| to minimise the imoact of kidney disease in its early stages.~·
33 II, 5. 7. 5| prevention, dialysis and kidney transplant.~· The Austrian
34 II, 5. 7. 6| system to provide support to kidney patients.~ ~Monitoring and
35 II, 5. 7. 7| Diabetes and Digestive and Kidney Diseases; 2005.~Ardissino
36 II, 5. 7. 7| al (2003): Prevalence of kidney damage in Australian adults:
37 II, 5. 7. 7| Australian adults: the AusDiab kidney study. J Am Soc Nephrol
38 II, 5. 7. 7| Prevalence of decreased kidney function in Chinese adults
39 II, 5. 7. 7| adults aged 35 to 74 years. Kidney Int 2005;68(6):2839-45.~
40 II, 5. 7. 7| disorders, and awareness. Kidney Int 2006 Aug;70(4):800-6.~
41 II, 5. 7. 7| DA, et al (2005): Chronic kidney disease awareness, prevalence,
42 II, 5. 7. 7| de Jong PE (2005): The kidney, a cardiovascular risk marker,
43 II, 5. 7. 7| new target for therapy. Kidney Int Suppl 2005 Sep;(98):
44 II, 5. 7. 7| adolescents with chronic kidney disease. Pediatr Nephrol
45 II, 5. 7. 7| Netherlands: hope for the future? Kidney Int Suppl 2004 Nov;(92):
46 II, 5. 7. 7| the general population. Kidney Int Suppl 2005 Apr;(94):
47 II, 5. 7. 7| Hsu CY (2004): Chronic kidney disease and the risks of
48 II, 5. 7. 7| estimates of utility in chronic kidney disease. Kidney Int 2005
49 II, 5. 7. 7| chronic kidney disease. Kidney Int 2005 Dec;68(6):2801-
50 II, 5. 7. 7| relationship of chronic kidney disease prevalence and ESRD
51 II, 5. 7. 7| Screening strategies for chronic kidney disease in the general population:
52 II, 5. 7. 7| in patients with chronic kidney disease: focus on end-stage
53 II, 5. 7. 7| and the risk for chronic kidney disease among nondiabetic
54 II, 5. 7. 7| risk factors in chronic kidney disease -- evaluating risk
55 II, 5. 7. 7| filtration rate in adults without kidney disease. J Am Soc Nephrol
56 II, 5. 7. 7| in children with chronic kidney disease-patient and caregiver
57 II, 5. 7. 7| Lowel H (2006): Chronic kidney disease and risk of incident
58 II, 5. 7. 7| 27(10):1245-50.~National Kidney Foundation. K/D The seventh
59 II, 5. 7. 7| recommendations for anemia in chronic kidney disease. Am J Kidney Dis
60 II, 5. 7. 7| chronic kidney disease. Am J Kidney Dis 2006;47(Suppl 3):S1-S145.~
61 II, 5. 7. 7| Suppl 3):S1-S145.~National Kidney Foundation. K/DOQI clinical
62 II, 5. 7. 7| practice guidelines for chronic kidney disease: evaluation, classification
63 II, 5. 7. 7| and stratification. Am J Kidney Dis 2002;39(Supple 1):S1-S266.~
64 II, 5. 7. 7| Supple 1):S1-S266.~National Kidney Foundation. K/DOQI clinical
65 II, 5. 7. 7| dyslipidemias in chronic kidney disease. Am J Kidney Dis
66 II, 5. 7. 7| chronic kidney disease. Am J Kidney Dis 2003;41(suppl 3):S1-S92.~
67 II, 5. 7. 7| suppl 3):S1-S92.~National Kidney Foundation. K/DOQI clinical
68 II, 5. 7. 7| metabolism and disease in chronic kidney disease. Am J Kidney Dis
69 II, 5. 7. 7| chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3):S1-S202.~
70 II, 5. 7. 7| Suppl 3):S1-S202.~National Kidney Foundation. K/DOQI clinical
71 II, 5. 7. 7| antihypertensive agents in chronic kidney disease. Am J Kidney Dis
72 II, 5. 7. 7| chronic kidney disease. Am J Kidney Dis 2004;43(Suppl 1):S1-S290.~
73 II, 5. 7. 7| Kausz AT (2002): Chronic kidney disease in the United States:
74 II, 5. 7. 7| pilot Spanish EPIRCE study. Kidney Int Suppl 2005 Dec;(99):
75 II, 5. 7. 7| Culleton B, Hamm LL, et al, Kidney disease as a risk factor
76 II, 5. 7. 7| Association Councils on Kidney in Cardiovascular Disease,
77 II, 5. 7. 7| medical care for chronic kidney disease and comorbidity
78 II, 5. 7. 7| R, et al (2007): Chronic kidney disease management in the
79 II, 5. 7. 7| NEOERICA project results. Kidney Int 2007 Jul;72(1):92-9.~
80 II, 5. 7. 7| M, et al (2006): Chronic kidney disease and mortality risk:
81 II, 9. 3. 1| prostate, testis, bowel, liver, kidney, oesophagus and pancreas.
82 III, 10. 2. 1| Leukemia*~Atherosclerosis*~Kidney and ureter~COPD, asthma
83 III, 10. 2. 1| Pancreas~- Urinary bladder~- Kidney (renal pelvis and renal
84 III, 10. 2. 1| and completed in liver and kidney. Therefore, under ideal
85 III, 10. 2. 5| many substances;~- deceased kidney haematic flow (about 1%
86 III, 10. 4. 2| animal feed~products~ ~ ~Kidney damage and~urinary tract
87 IV, 11. 5. 4| Europe represents 17% of kidney transplant activity and
88 Key, Ap5. 0. 0| kidney~kidneys~knee~knees~
